Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease

BACKGROUND: Approximately 15–20% of ulcerative colitis patients and 20–40% of those with Crohn’s disease experience extraintestinal manifestations (EIMs) of their inflammatory bowel disease (IBD). Clinicians who treat IBD must manage EIMs affecting multiple organs that variably correlate with intest...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleisher, Mark, Marsal, Jan, Lee, Scott D., Frado, Laura E., Parian, Alyssa, Korelitz, Burton I., Feagan, Brian G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5854745/
https://www.ncbi.nlm.nih.gov/pubmed/29484571
http://dx.doi.org/10.1007/s10620-018-4971-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5854745/
https://www.ncbi.nlm.nih.gov/pubmed/29484571
http://dx.doi.org/10.1007/s10620-018-4971-1

Ejemplares similares